- Ablynx (NASDAQ:ABLX) initiated with Buy rating and $26 (26% upside) price target by BofA/Merrill Lynch.
- Jazz Pharmaceuticals (NASDAQ:JAZZ) assumed with Neutral rating and $150 (11% upside) price target by H.C. Wainwright.
- Viking Therapeutics (NASDAQ:VKTX) assume with Buy rating and $7 (220% upside) price target by H.C. Wainwright.
- Teleflex (NYSE:TFX) resumed with Overweight rating and $295 (15% upside) price target by Piper Jaffray.
- Perrigo (NASDAQ:PRGO) upgraded to Sector Perform with an $86 (2% downside risk) price target by RBC.
- SAGE Therapeutics (NASDAQ:SAGE) price target raised to $100 (3% upside) from $86 by Needham on brexanolone upside. Upgraded to Buy with a $140 (45% upside) by Chardan Capital Markets.
- CVS Health (NYSE:CVS) upgraded to Buy with a $79 (14% upside) price target by Needham despite possible entry of Amazon into pharmacy. Risk/reward profile attractive.
- UBS AG (NYSE:UBS) upgraded to Buy by BofA/Merrill Lynch.
- AveXis (NASDAQ:AVXS) price target raised to $97 (2% downside risk) from $92 by RBC.
- Dynavax (NASDAQ:DVAX) price target raised to $25 (25% upside) from $24 by Cantor Fitzgerald after FDA OK of Heplisav-B.
- BioLife Solutions (NASDAQ:BLFS) price target raised to $8 (55% upside) from $7 Maxim Group. Shares up 18% premarket.
- Puma Biotech (NYSE:PBYI) price target raised to $164 (+29% upside) from $156 by Citigroup after Q3 results.
- Titan Pharmaceuticals (NASDAQ:TTNP) downgraded to Neutral with a $2 (27% upside) price target by Roth Capital.
- TrovaGene (NASDAQ:TROV) downgraded to Hold by Maxim Group citing its need to raise capital.
- Endo International (NASDAQ:ENDP) price target lowered to $7 (17% upside) from $9 by Cantor.